Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 29 of 961 for:    bone tumors AND NOT metastatic | Recruiting, Not yet recruiting, Available Studies

Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases (HIFU-Bone)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03479151
Recruitment Status : Recruiting
First Posted : March 27, 2018
Last Update Posted : August 8, 2018
Sponsor:
Collaborators:
Philips Medical Systems
Cancer Research UK
Information provided by (Responsible Party):
Nandita deSouza, Institute of Cancer Research, United Kingdom

Brief Summary:
The primary objective of this study is to determine whether intra- and post-procedural MR changes are indicative of reduction in pain symptom scores. The trial will recruit a cohort of patients with painful bone metastases, who wish to consider MRgHIFU treatment. These patients will be identified in conjunction with the pain and palliative care teams, as well as clinical and medical oncologists. Patients will undergo MRgHIFU treatment using scanning and treatment planning methods that have been established in the patients treated within the multi-centre study. The treatment response rate for the cohort will be recorded. Intra- and post-procedural imaging metrics will be evaluated for their ability to detect tissue changes, which may be indicative of response. Patients will be followed-up for up to 90 days after treatment, and will attend for repeat imaging and pain review at days 30, 60 and 90 after treatment. Any changes in imaging metrics will be compared between responders and non-responders.

Condition or disease Intervention/treatment Phase
Cancer Bone Metastases Device: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU) Not Applicable

Detailed Description:

The primary aim of this study is to investigate whether the ablated tissue volume indicated by immediate post-treatment Gd-T1W imaging is indicative of reduction in pain scores (response) 30 days after treatment.

The secondary aims of this study are:

  • To record the proportion of patients responding to MRgHIFU treatment at Days 7, 14, 30, 60 and 90 after treatment
  • To investigate whether intra-procedural PRFS metrics (thermal dose volume, temperature) are indicative of subsequent treatment response
  • To investigate whether intra- or post-procedural changes in ADC or T2 are indicative of subsequent treatment response
  • To record adverse events arising as a result of MRgHIFU treatment
  • To evaluate the effect of MRgHIFU treatment on patients' quality of life
  • To record the time to pain progression and the duration of pain response for patients in this cohort
  • To estimate the costs of MRgHIFU treatment

This is an exploratory study, which will recruit n=15 patients into one single cohort. Enrolment of the target population for the study is expected to take approximately 2 years. Patients will be eligible for the study if they wish to consider MRgHIFU treatment for pain palliation of a region of bony metastatic disease that is accessible to the MRgHIFU device. After providing their written informed consent to participate in the study, patients' suitability for treatment will be determined by a combined assessment of clinical review by a pain specialist, and an MR screening investigation to establish lesion targetability. Baseline clinical and imaging metrics will be recorded. Patients who fulfill all inclusion criteria, have none of the exclusion criteria, and who give informed consent, will be scheduled for MRgHIFU treatment to the target lesion. Treatment will be delivered under sedation on a day-case basis, according to protocols already established in our prior study. During treatment delivery, the investigators will assess imaging metrics of tissue change, which may be indicative of subsequent treatment response. Treatment would be expected to take approximately 1-2 hours, and after an observation period of approximately 2-4 hours, the patient will be discharged. Before discharge, follow-up instructions will be given to the patient. Patients' clinical and imaging responses to treatment will then be assessed at follow-up appointments up to 3 months after treatment.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases
Actual Study Start Date : March 16, 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MR-HIFU of painful bone metastases
Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases
Device: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
MRgHIFU treatment will be delivered using a Philips Sonalleve system, which integrates a high intensity phased array focused ultrasound transducer with our Philips 3T Achieva imaging system. An electromechanical transducer positioning system is used to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively. The MR system is used to provide images to plan the therapy, and to guide and monitor the thermal ablation with thermal imaging during the treatment.




Primary Outcome Measures :
  1. Measure the ablated tissue volume indicated by immediate post-treatment Gd-T1W imaging in responders and non-responders. [ Time Frame: Day 30 ]

Secondary Outcome Measures :
  1. To report the treatment response rate. [ Time Frame: up to 90 days ]
    Days 7, 14, 30, 60 and 90

  2. To investigate whether ablated tissue volume indicated by Gd-T1W imaging at Day 30 remains stable at Days 60 and 90. [ Time Frame: up to 90 days ]
  3. .To investigate whether intra-procedural PRFS metrics are different in responders and non-responders at Day 30 [ Time Frame: 30 days post treatment ]
    PRFS Metrics include thermal dose volume, temperature

  4. To investigate whether intra- or post-procedural changes in ADC are different in responders and non-responders. [ Time Frame: Day 30 ]
  5. To investigate whether intra- or post-procedural changes in T2 are different in responders and non-responders. [ Time Frame: Day 30 ]
  6. The rate of treatment-related adverse events [ Time Frame: up to 3 months after treatment. ]
  7. The effect of MRgHIFU treatment on patients' quality of life, recorded using Quality of Life Questionnaires (QLQ's). [ Time Frame: up to 3 months after treatment. ]
    using EORTC (European Organization for Research and Treatment of Cancer)- QLQ's

  8. The costs of MRgHIFU treatment. [ Time Frame: up to 3 months after treatment. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with painful bony metastatic disease
  • Target bony metastatic lesion is painful (NRS≥4)
  • Intended target region accessible for MRgHIFU treatment (usually not skull or spinal metastases above the sacrum)
  • Intended target region visible on non-contrast MR imaging

Exclusion Criteria:

  • MRI contra-indicated (e.g. by incompatible metal implants, claustrophobia, or because BMI precludes accommodation in the MR scanner)
  • Pregnancy
  • Sedation contra-indicated
  • Critical anatomical structure cannot be avoided along the beam path or the at the target (can be assessed at screening)
  • Internal or external fixation device along the beam path or at the target

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03479151


Contacts
Layout table for location contacts
Contact: Nandita deSouza, Professor 0208 661 3289 nandita.desouza@icr.ac.uk
Contact: Katherine May, BSc 02089156624 katherine.may@rmh.nhs.uk

Locations
Layout table for location information
United Kingdom
The Royal Marsden NHS Foundation Trust Recruiting
Sutton, Surrey, United Kingdom, SM2 5PT
Contact: Nandita deSouza, Professor    0208 661 3289    nandita.desouza@icr.ac.uk   
Contact: Katherine May, BSc    02089156624    katherine.may@rmh.nhs.uk   
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
Philips Medical Systems
Cancer Research UK
Investigators
Layout table for investigator information
Principal Investigator: Nandita deSouza, Professor Institute of Cancer Research, United Kingdom

Layout table for additonal information
Responsible Party: Nandita deSouza, Professor Nandita Da Souza, Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier: NCT03479151     History of Changes
Other Study ID Numbers: 17/LO/1689 CCR 4733
First Posted: March 27, 2018    Key Record Dates
Last Update Posted: August 8, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nandita deSouza, Institute of Cancer Research, United Kingdom:
Magnetic Resonance Imaging (MRI)
High Intensity Focused Ultrasound (HIFU)

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Bone Neoplasms
Bone Marrow Diseases
Neoplastic Processes
Neoplasms
Pathologic Processes
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases
Hematologic Diseases